{"id":"NCT02396316","sponsor":"Bayer","briefTitle":"Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients","officialTitle":"A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-02","primaryCompletion":"2016-06-16","completion":"2016-09-06","firstPosted":"2015-03-24","resultsPosted":"2017-07-21","lastUpdate":"2017-09-15"},"enrollment":54,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Neovascular"],"interventions":[{"type":"DRUG","name":"Aflibercept (Eylea, BAY 86-5321)","otherNames":[]},{"type":"DRUG","name":"Sham Injection","otherNames":[]}],"arms":[{"label":"Aflibercept","type":"EXPERIMENTAL"},{"label":"Sham Injection","type":"SHAM_COMPARATOR"}],"summary":"To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.","primaryOutcome":{"measure":"Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1","timeFrame":"From baseline to pre-dose at Week 1","effectByArm":[{"arm":"Aflibercept 2 mg Intravitreal (IVT) Injection Group","deltaMin":-8.5,"sd":8.7},{"arm":"Sham Injection Group","deltaMin":-4.9,"sd":10.8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0644"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":["37010901","33330958"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":27},"commonTop":["Punctate keratitis","Injection site pain","Conjunctival haemorrhage","Eye pain","Headache"]}}